Tradipitant (Nereus) for Motion Sickness
The Medical Letter on Drugs and Therapeutics · 22.06.2026 · 68 (1757) · 97-98
DOI: 10.58347/tml.2026.1757a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.06.2026.
Abstract (Originalsprache)
The FDA has approved the oral substance P/neurokinin-1 (NK-1) receptor antagonist tradipitant (Nereus – Vanda) for prevention of vomiting induced by motion in adults. Tradipitant is the first drug to be approved for motion sickness in more than 40 years. Other oral substance P/NK-1 receptor antagonists (i.e., aprepitant, rolapitant, and netupitant) have been available for years for prevention of chemotherapy-induced nausea and vomiting.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Tradipitant (Nereus) for Motion Sickness. The Medical Letter on Drugs and Therapeutics, 68(1757), 97-98. https://doi.org/10.58347/tml.2026.1757a
Vancouver
Tradipitant (Nereus) for Motion Sickness. The Medical Letter on Drugs and Therapeutics. 2026;68(1757):97-98. doi:10.58347/tml.2026.1757a
BibTeX
@article{euvimed2026,
title = {Tradipitant (Nereus) for Motion Sickness},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1757},
pages = {97--98},
doi = {10.58347/tml.2026.1757a}
}
EUVIMED